image: The TCT® Geoffrey O. Hartzler Master Operator Award will be presented to Kenneth Rosenfield, MD, MSc, during Transcatheter Cardiovascular Therapeutics® (TCT®), the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®). TCT® will take place October 25-28, 2025, in San Francisco, California at the Moscone Center.
Credit: CRF
NEW YORK – May 5, 2025 – The TCT® Geoffrey O. Hartzler Master Operator Award will be presented to Kenneth Rosenfield, MD, MSc, during Transcatheter Cardiovascular Therapeutics® (TCT®), the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®). TCT® will take place October 25-28, 2025, in San Francisco, California at the Moscone Center. The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and leadership.
Dr. Rosenfield is a distinguished interventional cardiologist and visionary leader with over 35 years of dedication to patient care and the advancement of cardiovascular disease treatment across the globe. He is widely recognized for his seminal work in endovascular therapy, pioneering innovative techniques and devices, and spearheading well-known initiatives that have left a lasting impact on the field. A dedicated educator and mentor, Dr. Rosenfield continues to shape the future of vascular medicine and inspire colleagues and trainees across disciplines internationally.
Specializing in complex cardiac and vascular interventions, he is a leader in treating carotid, kidney, and peripheral artery disease as well as complex venous thromboembolic diseases. Since 2002, Dr. Rosenfield has been a leading faculty member at the Massachusetts General Hospital (MGH), where he is the former Director of Invasive Cardiology. Currently he is Section Head for Vascular Medicine and Intervention, chairs the Acute Myocardial Infarction (STEMI) Committee, and maintains a faculty appointment at Harvard Medical School.
Dr. Rosenfield has contributed significantly to the field’s body of knowledge and approach to care. His contributions have led to practice changing findings including some of the earliest studies of intravascular ultrasound to understand vascular pathology, the development of self-expanding stents and drug coated balloons, the treatment of carotid stenosis, and the catheter based and team-based management of critical limb ischemia and pulmonary embolism. Most recently, he originated the concept of the Pulmonary Embolism Response Team (PERT) and implemented it with colleagues at MGH. He founded The National PERT Consortium™, a nonprofit designed to improve the management and outcomes of patients with PE. PERT has transformed the paradigm of care and now comprises physicians and health care professionals from all major medical institutions, engages in cutting-edge clinical trials, manages a research database, certifies hospital centers of excellence, and organizes a large annual international meeting on PE. In each of these domains of vascular medicine and interventional cardiology, Dr. Rosenfield has designed and served as international principal investigator for numerous landmark clinical trials, authoring 300+ peer-reviewed journal publications.
"The TCT® Master Operator Award is truly special to us because it reflects our core identity,” said Martin B. Leon, MD, Founder and Chairman Emeritus of CRF® and TCT® 2025 Program Director. “It honors the individual who, over the course of their career, has made such significant contributions as a proceduralist that they stand undeniably above their peers. Ken is that person – a unique figure whose dynamic leadership and unwavering mentorship have inspired and cultivated a loyal following among his fellows and colleagues. His influence has been instrumental in advancing the field of endovascular intervention in ways that will leave a lasting impact.”
"I am deeply honored and truly humbled to receive the TCT® Master Operator Award,” said Dr. Rosenfield. “Advancing vascular medicine and cardiovascular intervention through innovation and mentorship has been my life’s work. Teaching has always been a great passion and my most rewarding achievement is seeing my fellows grow and become leaders in the field. This award is not just a reflection of my work, but of the incredible individuals I’ve had the privilege to train and learn from throughout the years."
"Ken’s vision and pioneering contributions have not only transformed the treatment of cardiovascular disease but have also inspired generations of physicians,” said Sahil A. Parikh, MD, TCT® 2025 Program Director. “He embodies the very identity of our profession and is a driving force behind its dynamic evolution. Known and deeply respected for his mentorship, he has shaped the careers of countless fellows and colleagues – myself included – earning lasting admiration and leaving an indelible mark on vascular medicine."
“Ken has played a pivotal role in redefining interventional cardiology," said Juan F. Granada, MD, President and Chief Executive Officer of CRF® and TCT® 2025 Program Director. "Throughout his career, he has been a tireless educator, mentoring generations of physicians in the art and science of vascular intervention while his innovative spirit has led to groundbreaking advancements in the field.”
Dr. Rosenfield’s accolades reflect his remarkable career. In recognition of his extraordinary contributions, the PERT Consortium™ established the Dr. Kenneth Rosenfield Founder's Award and Keynote Lectureship. He also received the American Heart Association Laennec Master Clinician Award. He has held leadership roles as President of the Society for Cardiovascular Angiography & Interventions (SCAI) and the Massachusetts Chapter of the American College of Cardiology (ACC) where he also served on its Board of Governors. In addition, he is a founder and former board member of VIVA Physicians.
Dr. Rosenfield completed two fellowships: in interventional cardiology/vascular medicine at St. Elizabeth’s Medical Center in Boston, and in cardiovascular medicine at New England Medical Center (now Tufts Medical Center). He did his residency, including a Chief Resident year, at Kaiser San Francisco Medical Center. He earned his MD from the University of Massachusetts Medical School. He later got a Master of Science in healthcare delivery science from Dartmouth, from where he also graduated cum laude with a Bachelor of Arts in psychology.
Previous recipients of the TCT® Geoffrey O. Hartzler Master Operator Award include Eberhard Grube, MD; Hideo Tamai, MD; Osamu Katoh, MD; Takahiko Suzuki, MD; Horst Sievert, MD, PhD; Barry D. Rutherford, MD; Bernhard Meier, MD; Marie Claude Morice, MD; Paul S. Teirstein, MD; Patrick L. Whitlow, MD; Alec Vahanian, MD; John G. Webb, MD; Shigeru Saito, MD; Jean Fajadet, MD; William L. Lombardi, MD; and Jeffrey W. Moses, MD.
About CRF® and TCT®
The Cardiovascular Research Foundation® (CRF®) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF® not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF®’s centers of excellence include the CRF® Skirball Center for Innovation, CRF® Clinical Trials Center, CRF® Center for Education, CRF® Digital, TCTMD®, and Structural Heart: The Journal of the Heart Team.
Transcatheter Cardiovascular Therapeutics® (TCT®) is the annual scientific symposium of CRF® and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Anchored in a legacy spanning over three decades, TCT® is a world-class educational experience featuring disruptive innovation, scientific breakthroughs, expert-led tutorials, hands-on training, and ample opportunities for networking and collaboration.
For more information, visit www.crf.org and www.tctconference.com.
###